Odyssey Health receives $313,709 R&D rebate from Australian government for Phase I trial work

Odyssey Health, Inc.

Rebate of $313,709 ($468,727 AUD) received on November 18, 2022.
Funds are for clinical work conducted in Australia during fiscal year ended July 31, 2022.
Rebate relates to the Company's Phase I human clinical trial expenses.

item 8.01

Odyssey Health, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-008028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.